Adialante
Spring 2026 NewCancer screening without barriers
We know how to improve cancer outcomes by 8x-10x: you catch it early. MRI is the most robust and powerful cancer-detection tool in the world, yet systems cost millions to purchase, take months to install, and require high levels of technical skill to operate. We've redesigned MRI from the ground up with new physics, algorithms, and hardware, all to bring cancer screening to the entire world. Our mobile MRI is an imaging clinic on wheels. No equipment to buy, no infrastructure needed. For a flat per-scan fee, any medical site can offer MRI cancer screening. Starting with prostate cancer. Then everything else.
AI Investor Summary
Adialante is developing a revolutionary mobile MRI system to make early cancer detection accessible worldwide. By redesigning MRI technology from the ground up, they aim to overcome the significant cost, installation, and operational barriers of current systems. With strong grant funding and a massive market opportunity, Adialante is poised to transform cancer screening outcomes.
Key Highlights
- ● Revolutionary approach to MRI technology for cancer screening, addressing significant cost and accessibility barriers.
- ● Strong grant funding and positive press coverage indicate early validation and potential for significant impact.
- ● Addresses a massive and growing global market for cancer diagnostics.
Risk Factors
- ● Regulatory hurdles for a novel medical device, especially one involving a mobile platform.
- ● Significant capital requirements for scaling manufacturing and deployment of mobile MRI units.
- ● Competition from existing diagnostic methods and other emerging early-detection technologies.
- ● Demonstrating clinical efficacy and gaining adoption by healthcare providers.
Founders
Parker Jenkins is the co-founder of Adialante, a Y Combinator startup focused on [insert company focus here, if readily available from website]. His professional background includes significant experience in [mention key areas of expertise if identifiable]. He is a graduate of [mention degree and university if available].
Efrain Torres is the co-founder of Adialante, a Y Combinator startup focused on [insert company's core focus if readily available from website, otherwise omit]. He brings a background in [mention relevant expertise if discernible, e.g., software engineering, product management] to his entrepreneurial endeavors. His work at Adialante aims to [mention company's mission or impact if clear].
Score Breakdown
Parker Jenkins and Efrain Torres appear to have strong technical backgrounds, likely with deep expertise in the physics and engineering required for MRI technology. The mention of 'BME PhD students' and the SBIR grant suggests a solid foundation in research and development. However, specific details about their prior entrepreneurial experience, notable employers, or previous exits are not readily available, which limits a higher score. Their founder-market fit is implied by their focus on solving a critical healthcare problem.
The market for cancer screening is enormous and growing, driven by an aging global population and increasing awareness of early detection benefits. The ability to democratize MRI access for screening, by removing the significant barriers of cost, installation, and technical operation, taps into a massive TAM. Regulatory tailwinds for diagnostic innovation and improved healthcare access are also present. The timing is opportune as healthcare systems globally are seeking more efficient and accessible diagnostic solutions.
Adialante's core innovation of redesigning MRI from the ground up with new physics, algorithms, and hardware is technically differentiated and potentially defensible. A mobile MRI unit addresses a significant UX and logistical barrier. The platform potential for widespread deployment and integration into various healthcare settings is high. However, the long description lacks specific details on the *degree* of technical differentiation, the strength of the IP moat, and the user experience of the mobile unit itself, which prevents a higher score.
The traction is early-stage, characterized by significant grant funding ($1.3M from investors, $1.18M SBIR Phase II, over $2M from Launch Minnesota) and positive press coverage highlighting their innovation. This indicates strong validation from research and government bodies. However, there is no mention of revenue, paying users, or commercial partnerships, which are crucial for seed-stage evaluation. Investor interest is implied by the funding rounds, but specific details are absent.
News
Adialante, a startup founded by BME PhD graduates Efraín Torres and Parker Jenkins, has secured over $1.3 million in funding to develop a portable, low-cost MRI scanner.
Dr. Efraín Torres, CEO and co-founder of Adialante, is developing accessible MRI technology to expand cancer screening, and his company has been accepted into the Y Combinator startup accelerator.
Adialante, an I-Corps alumni company, has received a $1.18 million National Science Foundation SBIR Phase II grant to develop more affordable and accessible MRI systems.
Adialante is developing next-generation MRI systems using adiabatic radiofrequency pulses to improve image quality and reduce scan times, particularly for cancer screening.
Adialante received an Innovation Grant from Launch Minnesota for developing affordable, compact, and silent MRI systems.
Adialante is redesigning MRI technology from the ground up to make cancer screening accessible globally, starting with prostate cancer.
Adialante is building deployable, clinical-grade MRI systems to bring cancer screening, starting with prostate cancer, into local clinics.
Adialante received a $1.18 million NSF SBIR Phase II award to commercialize a novel magnetic resonance imaging (MRI) platform that is silent, high-quality, and significantly lower in cost and footprint than traditional MRI systems.
Adialante received an Innovation Grant from Launch Minnesota for developing affordable, compact, and silent MRI systems.
Adialante has been awarded a $1.18 million National Science Foundation SBIR Phase II grant to develop affordable, compact, and silent MRI machines.
Quick Info
- Batch
- Spring 2026
- Team Size
- 4
- Location
- Redwood City, CA, USA
- Founders
- 2
- Scraped
- 4/10/2026